ReviewCurrent opinion in allergy and clinical immunology2016
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Review in Current opinion in allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.International journal of chronic obstructive pulmonary disease · 2021Pooled it
- Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials.American journal of respiratory and critical care medicine · 2026Trial
- Reslizumab as add-on therapy in patients with refractory asthma.BMJ open respiratory research · 2020Trial
- Mast cell-derived extracellular vesicles in lung diseases: roles in pulmonary inflammation, immune regulation, and microenvironmental remodeling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Distinct miRNA expression patterns in circulating eosinophil subtypes and their subtype-derived exosomes in allergic asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Asthma and Allergic Bronchopulmonary Aspergillosis: Understanding, Insights, and State-of-the-Art.Journal of inflammation research · 2026Review
- Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy.Journal of asthma and allergy · 2026Article
- Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma.Scientific reports · 2025Article
- Phenotype Overlap and Lung Function in Childhood Asthma: The Interaction Between T2 and Non-T2 Responses.Pediatric pulmonology · 2025Observational
- Histamine as a mediator of cross-talk between human lung mast cells and macrophages.Scientific reports · 2025Article
- Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic Frontiers.Biomedicines · 2025Review
- Drug evaluation: mepolizumab in chronic obstructive pulmonary disease.Immunotherapy · 2025Review
- Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?Pulmonary therapy · 2025Review
- TSLP: contrasting roles in cancer.Frontiers in immunology · 2025Review
- Glucocorticoid Insensitivity in Severe Asthma: Underlying Molecular Mechanisms, Challenges, and Emerging Therapies.Archives of internal medicine research · 2025Article
- Personalized COPD Care: The Future of Precision-Based Therapies.Journal of clinical medicine · 2024Review
- Interleukin-5 alleviates cardiac remodelling via the STAT3 pathway in angiotensin II-infused mice.Journal of cellular and molecular medicine · 2024Article
- Management of Refractory Chronic Obstructive Pulmonary Disease: A Review.Life (Basel, Switzerland) · 2024Review
- Gαi1/3 signaling mediates IL-5-induced eosinophil activation and type 2 inflammation in eosinophilic chronic rhinosinusitis.Frontiers in immunology · 2024Article
- Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.Cancer science · 2023Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHuman eosinophils were first identified and named by Paul Ehrlich in 1879 on the basis of the cell's granular uptake of eosin. Although eosinophils represent approximately 1% of peripheral blood leukocytes, they have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophils and their mediators are critical effectors to asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Eosinophils are equipped with a large number of cell-surface receptors and produce specific cytokines and chemokines. RECENT
findingsEosinophils are the major source of interleukin-5 and highly express the interleukin-5Rα on their surface. Clinical trials evaluating monoclonal antibodies to interleukin-5 (mepolizumab and reslizumab) and its receptor interleukin-5Rα (benralizumab) have been or are underway in patients with eosinophilic asthma, EGPA and chronic obstructive pulmonary disease (COPD). Overall, targeting interleukin-5/interleukin-5Rα is associated with a marked decrease in blood and sputum eosinophilia, the number of exacerbations and improvement of some clinical parameters in adult patients with severe eosinophilic asthma. Pilot studies suggest that mepolizumab might be a glucocorticoid-sparing treatment in patients with EGPA. A preliminary study found that benralizumab did not reduce the exacerbations and did modify lung function in patients with eosinophilic COPD. SUMMARY: The review examines recent advances in the biology of eosinophils and how targeting the interleukin-5 pathway might offer benefit to some patients with severe asthma, EGPA, and COPD. Interleukin-5/interleukin-5Rα-targeted treatments offer promises to patients with eosinophilic respiratory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.